Rubifen Prolong® hard capsules of modified release EFG
Rubifen Prolong® hard capsules of modified release EFG
Laboratorios Rubió has been an influential figure in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Spain. In 1983, it launched the first medication for this disorder, Rubifen®, an immediate-release methylphenidate, marking a significant milestone in the national medical scene.
In January 2024, Laboratorios Rubió introduces Rubifen Prolong®, the first self-developed methylphenidate since the creation of Rubifen®. Rubifen Prolong® is a modified-release methylphenidate containing 50% immediate-release MTF and 50% extended-release MTF. It is indicated for the treatment of ADHD in children from 6 years of age, adolescents, and adults.
LINK TO TECHNICAL DATA SHEET
https://cima.aemps.es/cima/dochtml/ft/88838/FT_88838.html
LINK TO LEAFLET
https://cima.aemps.es/cima/pdfs/es/p/88839/88839_p.pdf
Presentations: 10, 20, 30, 40, and 60 mg in a 30-tablet format in boxes with child-proof safety blister packs.
Administration: orally once a day in the morning, with or without food. Swallow the capsule whole. It can also be opened and the contents poured into soft food (such as applesauce) and administered immediately. The mixture must be taken immediately and should not be heated, chewed, or crushed.
The recommended initial dose is 20 mg.
The maximum daily dose in children is 60 mg and 80 mg in adults.
